Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...